JENNIFER LOWERY

Well rounded nurse with over 6 years experience in direct patient care, including Critical Care, Research Coordination, and Hospice Care. Has a strong background in guiding teams, managing complex projects, and achieving strategic objectives. Excels in developing efficient processes, ensuring high standards, and aligning efforts with organizational goals and regulatory requirements. Known for collaborative approach and commitment to excellent patient care and safety.

• Collaborated with team of 15 in the development of Recover AUTO site workflow as Primary Research Coordinator.
• Achieved top site recognition by completing query resolution with accuracy and efficiency in a timely manner for Recover AUTO trial.
• Training - Trained team of nurses, research coordinators, and investigators in trial procedures and processes to ensure consistent quality of care.
• Patient Advocacy - Explained treatment procedures, medication risks, special diets and physician instructions to patients.

• Member of American Nurse Association
• Member of Emergency Nurse Association

• RN License, #913240, 12/26
• BLS, 06/26
• ACLS, 06/26
• NIHSS, 04/25
• CEN, 05/25
• USGPRIV, 2022
• CITI Training, 2023
• IATA Training, 2023
• CREW Training, 2023

• ATyr Pharma, Inc.: ATYR1923-C-004, A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients with Pulmonary Sarcoidosis (EFZO-FIT)
• Penumbra, Inc.: CLP 11899.B, MIND: A Prospective, Multicenter Study of Artemis, a Minimally Invasive Neuro Evacuation Device, in the Removal of Intracerebral Hemorrhage (MIND)
• Mitsubishi Tanabe Pharma Group: MT-3921-A01, A Phase 2a, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of MT-3921 in Subject with Acute Traumatic Cervical Spinal Cord Injury
• National Institutes of Health (NIH): RECOVER-AUTONOMIC, A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) (Recover AUTO)
• Pfizer: B0661037/CV185-325, A Randomized, Open-Label, Active Controlled, Safety and Descriptive Efficacy Study in Pediatric Subjects Requiring Anticoagulation for the Treatment of Venous Thromboembolic Event (Apixaban)
• Sanofi US Services Inc.: EFC17560, A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amitlemab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (COAST 2)
• US Endoscopy/STERIS, Cryospray Therapy for Benign Airway Stenosis: a pilot study (pilot-CRYSTASIS)
• Impact of Oral Immulina Supplementation on Natural Killer Cell Activities and Other Biomarkers Associated with Increasing Host Immune Resilience to Upper Respiratory Viruses in Normal Human Volunteers (Immulina Flu)
• University of Alabama at Birmingham: UAB2031, Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor α positive